FI3511004T3 - Yhdistelmävalmisteita syövän hoitoon - Google Patents
Yhdistelmävalmisteita syövän hoitoon Download PDFInfo
- Publication number
- FI3511004T3 FI3511004T3 FIEP19158672.6T FI19158672T FI3511004T3 FI 3511004 T3 FI3511004 T3 FI 3511004T3 FI 19158672 T FI19158672 T FI 19158672T FI 3511004 T3 FI3511004 T3 FI 3511004T3
- Authority
- FI
- Finland
- Prior art keywords
- lag
- protein
- derivative
- antineoplastic agent
- amino acid
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims 13
- 206010028980 Neoplasm Diseases 0.000 title claims 4
- 201000011510 cancer Diseases 0.000 title claims 4
- 102000017578 LAG3 Human genes 0.000 claims 32
- 101150030213 Lag3 gene Proteins 0.000 claims 32
- 229940034982 antineoplastic agent Drugs 0.000 claims 22
- 239000002246 antineoplastic agent Substances 0.000 claims 22
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 20
- 150000001413 amino acids Chemical class 0.000 claims 16
- 229910052697 platinum Inorganic materials 0.000 claims 10
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 8
- 229940056913 eftilagimod alfa Drugs 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 108020001580 protein domains Proteins 0.000 claims 6
- 101710183280 Topoisomerase Proteins 0.000 claims 5
- 229960004562 carboplatin Drugs 0.000 claims 5
- 190000008236 carboplatin Chemical compound 0.000 claims 5
- 229960001756 oxaliplatin Drugs 0.000 claims 5
- 102000043131 MHC class II family Human genes 0.000 claims 4
- 108091054438 MHC class II family Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 229960000303 topotecan Drugs 0.000 claims 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 3
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 229950007221 nedaplatin Drugs 0.000 claims 2
- 190000005734 nedaplatin Chemical compound 0.000 claims 2
- 229950005566 picoplatin Drugs 0.000 claims 2
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims 2
- 229960005399 satraplatin Drugs 0.000 claims 2
- 190014017285 satraplatin Chemical compound 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (25)
1. Yhdistelmävalmiste, joka käsittää (a) LAG-3-proteiinin johdannaista, joka pystyy sitoutumaan MHC-luokan II molekyyleihin; ja (b) antineoplastista ainetta, jolloin antineoplastinen aine on platinapohjainen antineoplastinen aine tai topoisomeraasi | -estäjä; jolloin LAG-3-proteiinin johdannainen käsittää ihmisen LAG-3-proteiinin domeenin D1 30 aminohapon silmukan ulkopuolisen sekvenssin GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY (SEQ ID NO:2); tai ihmisen LAG-3-proteiinin domeenin D1 30 aminohapon silmukan ulkopuolisen sekvenssin GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY (SEQ ID NO:2) variantin, jolloin variantti käsittää yhden tai useamman konservatiivisen aminohapposubstituution ja se on vähintään 70-prosenttisesti identtinen aminohappokoostumukseltaan 30 aminohapon silmukan ulkopuolisen sekvenssin kanssa.
2. Patenttivaatimuksen 1 mukainen yhdistelmävalmiste LAG-3-proteiinin johdannaisen ja antineoplastisen aineen antamiseksi yhdessä tai peräkkäin.
3. Patenttivaatimuksen 1 tai 2 mukainen yhdistelmävalmiste, jossa LAG-3- — proteiinin johdannainen on erillään antineoplastisesta aineesta.
4. Jonkin edellisen patenttivaatimuksen mukainen yhdistelmävalmiste, jossa LAG-3-proteiinin johdannaista on annoksena, joka vastaa molaarisesti 0,25— 30 mg:aa LAG-3lg-fuusioproteiinia IMP321.
5. Jonkin edellisen patenttivaatimuksen mukainen yhdistelmävalmiste, joka — käsittää useita annoksia LAG-3-proteiinin johdannaista ja/tai useita annoksia antineoplastista ainetta.
2 EP3 511 004
6. Jonkin edellisen patenttivaatimuksen mukainen yhdistelmävalmiste, jossa platinapohjainen antineoplastinen aine käsittää sisplatiinin, karboplatiinin, oksaliplatiinin, satraplatiinin, pikoplatiinin, nedaplatiinin tai triplatiinin.
7. Jonkin edellisen patenttivaatimuksen mukainen yhdistelmävalmiste, jossa platinapohjainen antineoplastinen aine käsittää oksaliplatiinin tai karboplatiinin.
8. Jonkin patenttivaatimuksen 1-5 mukainen yhdistelmävalmiste, jossa topoisomeraasi I:n estäjä käsittää topotekaanin.
9. Jonkin edeltävän patenttivaatimuksen mukainen yhdistelmävalmiste, jossa LAG-3-proteiinin johdannainen on fuusioitu immunoglobuliinin Fc-sekvenssiin.
10. Jonkin edellisen patenttivaatimuksen mukainen yhdistelmävalmiste, jossa LAG-3-proteiinin johdannainen on IMP321.
11. Lääkekoostumus, joka käsittää (a) LAG-3-proteiinin johdannaista, joka pystyy sitoutumaan MHC-luokan II molekyyleihin; ja (b) antineoplastista ainetta, jolloin antineoplastinen aine on platinapohjainen antineoplastinen aine tai topoisomeraasi | -estäjä; jolloin LAG-3-proteiinin johdannainen käsittää ihmisen LAG-3-proteiinin domeenin D1 30 aminohapon silmukan ulkopuolisen sekvenssin GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY (SEQ ID NO:2); tai ihmisen LAG-3-proteiinin domeenin D1 30 aminohapon silmukan ulkopuolisen sekvenssin GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY (SEQ ID NO:2) variantin, jolloin variantti käsittää yhden tai useamman konservatiivisen aminohapposubstituution ja se on vähintään 70-prosenttisesti identtinen aminohappokoostumukseltaan 30 aminohapon silmukan ulkopuolisen sekvenssin kanssa; ja
3 EP3 511 004 (c) farmaseuttisesti hyväksyttävää kantoainetta, apuainetta tai laimennusainetta.
12. Jonkin patenttivaatimuksen 1-10 mukainen yhdistelmävalmiste tai patenttivaatimuksen 11 mukainen lääkekoostumus käytettäväksi lääkkeenä.
13. Jonkin patenttivaatimuksen 1-10 mukainen yhdistelmävalmiste tai patenttivaatimuksen 11 mukainen lääkekoostumus käytettäväksi syövän ehkäisyssä, hoidossa tai parantamisessa.
14. LAG-3-proteiini tai sen johdannainen, joka pystyy sitoutumaan MHC- luokan II molekyyleihin, ja antineoplastinen aine käytettäväksi syövän ehkäisyssä, hoidossa tai parantamisessa, jolloin antineoplastinen aine on platinapohjainen antineoplastinen aine tai topoisomeraasi | -estäjä ja jolloin LAG-3-proteiinin johdannainen käsittää ihmisen LAG-3-proteiinin domeenin D1 30 aminohapon silmukan ulkopuolisen sekvenssin GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY (SEQ ID NO:2); tai ihmisen LAG-3-proteiinin domeenin D1 30 aminohapon silmukan ulkopuolisen sekvenssin GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY (SEQ ID NO:2) variantin, jolloin variantti käsittää yhden tai useamman konservatiivisen aminohapposubstituution ja se on vähintään 70-prosenttisesti identtinen aminohappokoostumukseltaan 30 aminohapon silmukan ulkopuolisen sekvenssin kanssa.
15. LAG-3-proteiini tai sen johdannainen, joka pystyy sitoutumaan MHC- luokan II molekyyleihin, käytettäväksi syövän ehkäisyssä, hoidossa tai parantamisessa, jolloin LAG-3-proteiinia tai sen johdannaista on tarkoitus antaa samanaikaisesti tai peräkkäin antineoplastisen aineen kanssa, jolloin antineoplastinen aine on platinapohjainen antineoplastinen aine tai topoisomeraasi I:n estäjä ja jolloin LAG-3-proteiinin johdannainen käsittää ihmisen LAG-3-proteiinin domeenin D1 30 aminohapon silmukan ulkopuolisen sekvenssin GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY (SEQ ID NO:2); tai
4 EP3 511 004 ihmisen LAG-3-proteiinin domeenin D1 30 aminohapon silmukan ulkopuolisen sekvenssin GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY (SEQ ID NO:2) variantin, jolloin variantti käsittää yhden tai useamman konservatiivisen aminohapposubstituution ja se on vähintään 70-prosenttisesti identtinen aminohappokoostumukseltaan 30 aminohapon silmukan ulkopuolisen sekvenssin kanssa.
16. Patenttivaatimuksen 14 tai 15 mukaisesti käytettävä LAG-3-proteiini tai sen johdannainen, jolloin LAG-3-proteiinia tai sen johdannaista on tarkoitus antaa annoksena, joka vastaa molaarisesti 0,25-30 mg:aa LAG-3lg- fuusioproteiinia IMP321.
17. Jonkin patenttivaatimuksen 14-16 mukaisesti käytettävä LAG-3-proteiini tai sen johdannainen, jolloin LAG-3-proteiinia tai sen johdannaista tulee antaa useina annoksina ja/tai antineoplastista ainetta tulee antaa useina annoksina.
18. Jonkin patenttivaatimuksen 14—17 mukaisesti käytettävä LAG-3-proteiini taisenjohdannainen, jolloin platinapohjainen antineoplastinen aine käsittää sisplatiinin, karboplatiinin, oksaliplatiinin, satraplatiinin, pikoplatiinin, nedaplatiinin tai triplatiinin.
19. Jonkin patenttivaatimuksen 14—18 mukaisesti käytettävä LAG-3-proteiini tai sen johdannainen, jolloin platinapohjainen antineoplastinen aine käsittää — oksaliplatiinin tai karboplatiinin.
20. Jonkin patenttivaatimuksen 14—17 mukaisesti käytettävä LAG-3-proteiini tai sen johdannainen, jolloin topoisomeraasi | -estäjä käsittää topotekaanin.
21. Jonkin patenttivaatimuksen 14-20 mukaisesti käytettävä LAG-3-proteiini tai sen johdannainen, jolloin LAG-3-proteiinin johdannainen on fuusioitu immunoglobuliinin Fc-sekvenssiin.
22. Jonkin patenttivaatimuksen 14-21 mukaisesti käytettävä LAG-3-proteiini tai sen johdannainen, jolloin LAG-3-proteiinin johdannainen on IMP321.
EP3 511 004
23. Jonkin patenttivaatimuksen 14-17 mukaisesti käytettävä LAG-3-proteiini tai sen johdannainen, jolloin LAG-3-proteiinin johdannainen on IMP321 ja platinapohjainen antineoplastinen aine käsittää oksaliplatiinin.
24. Jonkin patenttivaatimuksen 14—17 mukaisesti käytettävä LAG-3-proteiini 5 taisenjohdannainen, jolloin LAG-3-proteiinin johdannainen on IMP321 ja platinapohjainen antineoplastinen aine käsittää karboplatiinin.
25. Jonkin patenttivaatimuksen 14—17 mukaisesti käytettävä LAG-3-proteiini tai sen johdannainen, jolloin LAG-3-proteiinin johdannainen on IMP321 ja topoisomeraasi | -estäjä käsittää topotekaanin.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322626.1A GB201322626D0 (en) | 2013-12-19 | 2013-12-19 | Combined preparations for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3511004T3 true FI3511004T3 (fi) | 2024-09-25 |
Family
ID=50071175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19158672.6T FI3511004T3 (fi) | 2013-12-19 | 2014-12-19 | Yhdistelmävalmisteita syövän hoitoon |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10736940B2 (fi) |
| EP (3) | EP4414035A3 (fi) |
| JP (2) | JP6691054B2 (fi) |
| KR (3) | KR102593917B1 (fi) |
| CN (2) | CN105916504B (fi) |
| AU (1) | AU2014368420B2 (fi) |
| DK (2) | DK3511004T3 (fi) |
| ES (2) | ES2730976T3 (fi) |
| FI (1) | FI3511004T3 (fi) |
| GB (1) | GB201322626D0 (fi) |
| PL (2) | PL3089749T3 (fi) |
| PT (2) | PT3089749T (fi) |
| TR (1) | TR201910866T4 (fi) |
| WO (1) | WO2015091970A1 (fi) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| US10265379B2 (en) * | 2015-09-16 | 2019-04-23 | Annabelle Rodriguez Oquendo | Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| MX2018007406A (es) | 2015-12-16 | 2018-08-15 | Merck Sharp & Dohme | Anticuerpos anti-lag3 y fragmentos de enlace al antigeno. |
| CN108204958A (zh) * | 2016-12-19 | 2018-06-26 | 伊缪泰普有限公司 | 结合测定 |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| EP4157879A4 (en) | 2020-05-27 | 2024-06-19 | Agilent Technologies, Inc. | Anti-human lag-3 antibodies and their use in immunohistochemistry (ihc) |
| MX2022014909A (es) * | 2020-05-28 | 2023-03-06 | Immutep Sas | Tratamiento del cáncer. |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| US5098702A (en) | 1986-04-09 | 1992-03-24 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
| CA1341281C (en) | 1986-07-09 | 2001-08-07 | Hubert J.P. Schoemaker | Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen |
| US5785973A (en) | 1988-02-01 | 1998-07-28 | Praxis Biologics, Inc. | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines |
| EP0432216A1 (en) | 1988-09-01 | 1991-06-19 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| JPH04504416A (ja) | 1989-02-17 | 1992-08-06 | コセルコ・ミモトープス・ピィ・ティ・ワイ．エル・ティ・ディ． | ペプチドの使用方法と合成方法 |
| US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| JP3051411B2 (ja) | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | 新規ｄｎａならびにそれを含有する発現プラスミド |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
| FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US7294712B2 (en) | 1990-06-04 | 2007-11-13 | Aventis Pharma S.A. | Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses |
| US5981276A (en) | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| DK0551401T3 (da) | 1990-09-14 | 1996-01-22 | Univ Texas | Fremgangsmåde og præparater til genterapi og potensering af antitumor-immunitet |
| JP3459268B2 (ja) | 1990-09-17 | 2003-10-20 | 中外製薬株式会社 | 抗癌剤 |
| EP1721978B1 (fr) | 1991-02-08 | 2011-04-06 | Aventis Pharma S.A. | Séquences nucléotidiques codant pour des régions variables de chaines alpha des récepteurs des lymphocytes humains ainsi que leurs applications |
| US6596536B1 (en) | 1991-02-08 | 2003-07-22 | Aventis Pharma S.A. | Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses |
| CA2079881C (fr) | 1991-02-12 | 2007-11-06 | Thierry Hercend | Sequences nucleotidiques codant pour des regions variables de chaines .beta. des recepteurs des lymphocytes t humains, segments peptidiques correspondants et les applications diagnostiques et therapeutiques |
| US5904920A (en) | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
| US5637483A (en) | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
| US6506604B2 (en) | 1993-06-11 | 2003-01-14 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| ES2281899T3 (es) | 1994-05-06 | 2007-10-01 | Institut Gustave Roussy | Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica; anticuerpo anti-idiotipo. |
| US5872005A (en) | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| US6040183A (en) | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
| US6033674A (en) | 1995-12-28 | 2000-03-07 | Johns Hopkins University School Of Medicine | Method of treating cancer with a tumor cell line having modified cytokine expression |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
| IL130123A (en) | 1996-11-28 | 2007-07-24 | Roussy Inst Gustave | LAG-3 protein mutants, their expression, use and method of production |
| UA73270C2 (en) | 1996-11-29 | 2005-07-15 | Application of genetically structured cells expressing lymphocytes activation gene (lag-3) on the surface for protection of transplant against rejection and a method for induction of specific protection against rejection of material being tranplanted | |
| DE69824859T2 (de) | 1997-04-14 | 2005-08-04 | Cell Genesys, Inc., Foster City | Methoden zur erhöhung der effizienz rekombinanter aav produkte |
| EP0893507A1 (en) | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
| US6037177A (en) | 1997-08-08 | 2000-03-14 | Cell Genesys, Inc. | Method for increasing the efficiency of recombinant AAV production |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| AU741602B2 (en) | 1998-02-02 | 2001-12-06 | Johns Hopkins University School Of Medicine, The | A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use |
| FR2777890B1 (fr) | 1998-04-22 | 2000-12-29 | Roussy Inst Gustave | Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer |
| AU5458500A (en) | 1999-06-02 | 2000-12-18 | Cell Genesys, Inc. | Regulation of systemic immune responses utilizing cytokines and antigens |
| FR2795415B1 (fr) | 1999-06-28 | 2003-09-05 | Roussy Inst Gustave | Compose peptidique derive d'une orf decalee du gene ice |
| AT409086B (de) | 1999-11-16 | 2002-05-27 | Igeneon Krebs Immuntherapie | Neue verwendung von antikörpern als impfstoffe |
| JP2004508290A (ja) | 2000-04-26 | 2004-03-18 | バイオベクター セラピューティクス | 免疫調節における粒状ベクターの使用 |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| ATE519779T1 (de) | 2001-09-19 | 2011-08-15 | Roussy Inst Gustave | An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen |
| CA2752140A1 (en) | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| EP1675596A4 (en) | 2003-10-10 | 2009-01-21 | Powderject Vaccines Inc | METHOD |
| FR2868781B1 (fr) | 2004-04-13 | 2008-02-22 | Immutep | Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations |
| JP2006124383A (ja) | 2004-09-30 | 2006-05-18 | Kobayashi Pharmaceut Co Ltd | 樹状細胞活性化剤 |
| JP2006141346A (ja) | 2004-11-24 | 2006-06-08 | Kobayashi Pharmaceut Co Ltd | 樹状細胞活性化剤 |
| US7964571B2 (en) * | 2004-12-09 | 2011-06-21 | Egen, Inc. | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
| US20070231298A1 (en) | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
| US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| WO2009032256A2 (en) | 2007-08-30 | 2009-03-12 | Cell Genesys, Inc. | Apc activators in combination with a cytokine-secreting cell and methods of use thereof |
| EP2044949A1 (en) * | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| BR112013014076A2 (pt) | 2010-12-06 | 2016-11-22 | Cure Cancer Worldwide Corp | métodos de direcionamento metabólico de células de câncer usando quimio- e imunotherapia para tratamento de câncer |
| US9220776B2 (en) | 2011-03-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
| KR20140126357A (ko) | 2012-02-01 | 2014-10-30 | 컴퓨젠 엘티디. | C1orf32 항체 및 이의 암 치료를 위한 용도 |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
| WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
| US10081681B2 (en) | 2013-09-20 | 2018-09-25 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| WO2015131176A1 (en) | 2014-02-28 | 2015-09-03 | Podack Eckhard R | Compositions, methods, and kits for treatment of cancer |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
-
2013
- 2013-12-19 GB GBGB1322626.1A patent/GB201322626D0/en not_active Ceased
-
2014
- 2014-12-19 ES ES14830806T patent/ES2730976T3/es active Active
- 2014-12-19 EP EP24178618.5A patent/EP4414035A3/en active Pending
- 2014-12-19 EP EP14830806.7A patent/EP3089749B1/en active Active
- 2014-12-19 KR KR1020227025903A patent/KR102593917B1/ko active Active
- 2014-12-19 KR KR1020227014127A patent/KR102441425B1/ko active Active
- 2014-12-19 PT PT14830806T patent/PT3089749T/pt unknown
- 2014-12-19 DK DK19158672.6T patent/DK3511004T3/da active
- 2014-12-19 EP EP19158672.6A patent/EP3511004B1/en active Active
- 2014-12-19 PT PT191586726T patent/PT3511004T/pt unknown
- 2014-12-19 KR KR1020167019272A patent/KR20160093076A/ko not_active Ceased
- 2014-12-19 JP JP2016559686A patent/JP6691054B2/ja active Active
- 2014-12-19 DK DK14830806.7T patent/DK3089749T3/da active
- 2014-12-19 PL PL14830806T patent/PL3089749T3/pl unknown
- 2014-12-19 WO PCT/EP2014/078779 patent/WO2015091970A1/en not_active Ceased
- 2014-12-19 CN CN201480073584.3A patent/CN105916504B/zh active Active
- 2014-12-19 PL PL19158672.6T patent/PL3511004T3/pl unknown
- 2014-12-19 FI FIEP19158672.6T patent/FI3511004T3/fi active
- 2014-12-19 US US15/105,789 patent/US10736940B2/en active Active
- 2014-12-19 CN CN202110293412.9A patent/CN112957452A/zh active Pending
- 2014-12-19 TR TR2019/10866T patent/TR201910866T4/tr unknown
- 2014-12-19 AU AU2014368420A patent/AU2014368420B2/en active Active
- 2014-12-19 ES ES19158672T patent/ES2986949T3/es active Active
-
2019
- 2019-09-09 JP JP2019163672A patent/JP7160345B2/ja active Active
-
2020
- 2020-07-01 US US16/918,527 patent/US12214012B2/en active Active
-
2024
- 2024-12-24 US US19/000,820 patent/US20250127856A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3511004T3 (fi) | Yhdistelmävalmisteita syövän hoitoon | |
| JP2015518818A5 (fi) | ||
| EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
| EA201491299A1 (ru) | Карбаматные соединения, их получение и применение | |
| JP2015517488A5 (fi) | ||
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| NZ763123A (en) | Pde9 inhibitor and use thereof | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2017503014A5 (fi) | ||
| JP2016530280A5 (fi) | ||
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| BR112016012506A8 (pt) | combinações farmacêuticas, seus usos, e uso de um portador de dados | |
| JP2019203035A5 (fi) | ||
| DOP2011000343A (es) | Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral | |
| CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| CR20140540A (es) | Nueva forma de dosificación y formulación de abediterol | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| HRP20181021T1 (hr) | Formulacija za bispecifične aktivatore limfocita t (bites) | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| BR112019002655A2 (pt) | composto, intermediário de síntese, uso e composição farmacêutica neuromoduladora | |
| RU2015113031A (ru) | Использование 3-n-бутил изоиндолин кетонов при приготовлении лекарственных средств для профилактики и лечения церебрального инфаркта | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. |